An insider’s view on
drug development in NASH
with Dimitar Tonev

With a 23-year career as a hepatologist, Dimitar Tonev specialises in innovations and disease-modifying therapies in nonalcoholic steatohepatitis (NASH). In this webinar he discusses the NASH therapy landscape, the importance of genetics in trial recruitment, and the controversial topics that should be addressed to bring real improvements to NASH patients.


Our panel of experts


Dimitar Tonev-1

Dimitar Tonev

Independent Consultant